BD (NYSE: BDX) today said it has appointed Christopher DelOrefice as executive VP and chief financial officer, effective Sept. 6.

DelOrefice currently serves as the VP of investor relations at Johnson & Johnson and has held numerous leadership roles within the company for more than 20 years. Prior to joining J&J, DelOrefice held leadership positions at AstraZeneca Pharmaceuticals, AET Films and Ametek.

“Chris has the right mix of strong operational and corporate finance experience that is highly relevant to his new role as CFO at BD,” president and CEO Tom Polen said in a news release. “His deep experience in health care and medical technology — including supporting multiple large businesses and functions at J&J — will help create a seamless transition as CFO. His investor relations expertise provides additional value to the investment community who know him well. Chris’s track record leading and developing strong finance teams will be an asset to BD.”

DelOrefice will replace Christopher Reidy, who recently announced his intent to retire from BD. He will be responsible for the global finance organization at the Franklin Lakes, N.J.-based company, and Reidy will transition the leadership of BD’s technology and global services organization by the end of the calendar year.

“It is an exciting time to be joining BD as it continues to evolve into one of the most relevant global medical technology companies in the world,” said DelOrefice. “The positive impact on the lives of patients worldwide and its ability to make meaningful progress on some of the most challenging global health issues of our time make BD truly unique in the medical technology industry. I look forward to helping the BD team drive its 2025 growth strategy, optimize its margins and continue to generate shareholder value.”